Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Picroside II is a flavonoid that has been isolated from P. kurroa and has diverse biological activities.1,2,3,4 It decreases expression of FATP5 and SCD, encoding fatty acid transport protein 5 and steroyl CoA desaturase, respectively, and inhibits free fatty acid-induced lipid accumulation in HepG2 cells when used at a concentration of 10 µM.1 Picroside II inhibits RANKL-induced osteoclast formation in isolated murine bone marrow cells and decreases the size of bone resorption pits in bovine bone slices.2 In vivo, picroside II (10 and 60 mg/kg) inhibits LPS-induced trabecular bone loss in a mouse model of inflammatory osteoporosis. It prevents ischemia-reperfusion-induced testicular apoptosis and malondialdehyde (MDA) production in a rat model of testicular torsion.3 Picroside II also reduces airway inflammation, lung mucus hypersecretion, and bronchoalveolar lavage fluid (BALF) inflammatory cell infiltration in a mouse model of house dust mite-induced allergic asthma.4
WARNING This product is not for human or veterinary use.
1. Picroside II attenuates fatty acid accumulation in HepG2 cells via modulation of fatty acid uptake and synthesis. Clin. Mol. Hepatol. 24(1), 77-87 (2018).
2. Picroside II inhibits RANKL-
3. Picroside II attenuates ischemia/reperfusion testicular injury by alleviating oxidative stress and apoptosis through reducing nitric oxide synthesis. Acta Cir. Bras. 34(11), e201901102 (2019).
4. Picroside II attenuates airway inflammation by downregulating the transcription factor GATA3 and Th2-